Form 4: Revolution Medicines' General Counsel Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Jeff Cislini, General Counsel of Revolution Medicines, sold a total of 1,500 shares of common stock on March 27, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Jeff Cislini, the General Counsel of Revolution Medicines, sold 700 shares of common stock at a weighted average price of $30.3843 on March 27, 2024.
- He also sold 800 shares of common stock at a weighted average price of $31.515 on the same day.
- These transactions were executed under a 10b5-1 trading plan adopted on March 27, 2023.
- Following these transactions, Cislini beneficially owns 54,374 shares of Revolution Medicines, Inc., including 48,972 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock sales by an insider under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The stock sale by a company insider could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 03/27/2023 | Date of adoption of the 10b5-1 trading plan. |
| 03/27/2024 | Date of the stock sale transactions. |
| 03/28/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.